



الجمهورية الجزائرية الديمقراطية الشعبية

People's Democratic Republic of Algeria

وزارة التعليم العالي والبحث العلمي

Ministry of Higher Education and Scientific Research



University of Brothers Mentouri Constantine 1

Faculty of Natural Sciences and Life

جامعة الإخوة منتوري قسنطينة 1

كلية علوم الطبيعة والحياة

قسم الكيمياء الحيوية والبيولوجيا الخلوية والجزيئية

Department of Biochemistry /Molecular and Cellular Biology

## Dissertation

To Get a Diploma of Master in Biochemistry

Option: Molecular Nutrition and Health

Entitled:

**Anti-Obesity Effect of Olive Leaves Powder**

**Done by:**

ATHAMNA Fatima

BENOUCHENNE Djamila

Date of presentation: July 6<sup>TH</sup>, 2017

**Examination board:**

**President:** Prof. Y. NECIB

Pr. University of Brothers MENTOURI Constantine 1

**Supervisor:** Dr. A. KHEDARA

M. C. A University of Brothers MENTOURI Constantine 1

**Examiner:** Dr. T. NOUADRI

M. C. A. University of Brothers MENTOURI Constantine 1

**Academic year**

2016-2017

## DEDICATION

I dedicate my dissertation work to my family and friends.

Special feelings of gratitude to my loving parents, for their continual faithful support during my study.

Thanks and gratitude is also extended, to my sisters Sihem, Mounira, Djohayna, and Rouaida. my uncles Ryad and Hakim, my aunts, Naima, Dalila, Khadra and Alya And my fiance Bilale.

I also pay thankfulness to my best friends; Fatima, Amina, Hadjer, Chayma, Kenza, and Rokia.

Finally, I pray that Allah accept this effort and make it of real benefit to all who read it.

*Djamila*

## DEDICATION

I dedicate my dissertation work to my family and friends.

A special feeling of gratitude to my loving parents, to my husband for their continual faithful support during my study.

Thanks and gratitude are also extended, to my sisters Fayza, Naziha,  
Sonya

And to my brothers: Walid, Abd El wakil, Kamel

I also pay thankfulness to my best friends: Djamila, Imen, Amina,  
Hadjer, Chayma, Kenza.

Finally, I pray that Allah accept this effort and make it of real benefit  
to all who read it.

*Fatima*

## LIST OF FIGURES

**Figure 1.** Prevalence of obesity, ages 18+, both sexes, 2014 (age-standardized estimates)

source: WHO

**Figure 2.** The relationship between obesity and dyslipidemia

**Figure 3.** *Olea europaea* tree variety *Chemlali*

**Figure 4.** *Olea europaea* variety *Chemlali* leaves

**Figure 5.** The effect of 6.25% of olive leaves powder on final body weight

**Figure 6.** The effect of 6.25% of olive leaves powder on gain body weight

**Figure 7.** The effect of 6.25% of olive leaves powder on Relative Liver Weight

**Figure 8.** The effect of 6.25% of olive leaves powder on Kidney Weight

**Figure 9.** The effect of 6.25% of olive leaves powder on serum glucose concentration

**Figure 10 .** The effect of 6.25 % of olive leaves powder on serum cholesterol concentration

**Figure 11.** The effect of 6.25% of olive leaves powder on serum triglyceride

**Figure 12.** The effect of 6.25% of olive leaves powder on and perirenal adipose tissue

**Figure 13.** The effect of 6.25% of olive leaves powder on epididimal adipose tissue

**Figure 14:** The effect of 6.25% of olive leaves powder on serum albumin

**Figure 15:** The effect of 6.25% of olive leaves powder on serum creatinine

## LIST OF TABLES

- Table 1.** Cut points of BMI for the classification of obesity
- Table 2.** Waist circumference thresholds for abdominal obesity
- Table 3.** Adipokines profile in obesity
- Table 4.** The polyphenol compounds present in olive leaves
- Table 5.** Fatty acids composition in OL of variety *chemlali*
- Table 6.** Fibers composition of olive leaves
- Table 7.** Mineral composition of olive leaves Variety *Chemlali*
- Table 8.** Pigments composition in olive leaves
- Table 9.** Composition of basal diets

## ABBREVIATIONS

**4-AP:** phenol, 4 – aminophenazone

**ADP:** adenosine-5-diphosphate

**AMPK:** Adenosine Monophosphat Protein Kinase

**AMPK:** AMP-activated protein Kinase

**ATP:** adenosine-5-triphosphate

**BMI:** Body Mass Index

**BP:** blood pressure

**C:** Control

**CETP:** Cholesteryl Ester Transfer Protein

**CHE:** Cholesterol esterase

**CHOD:** Cholesterol oxidase

**CNS:** Central Nervous System

**DAP:** dihydroxyacetone phosphate

**F&V:** Vegetables and Fruits

**FFA:** Free Fatty Acid

**G3P:** Glycerol-3-Phosphate

**G6PD:** Glucose-6-Phosphate Deshydrogenase

**GOD:** Glucose Oxidase

**H<sub>2</sub>O<sub>2</sub>:** Hydrogen peroxide

**HDL-C:** High Density Lipoprotein

**HMPC:** Committee on Herbal Medicinal Products

**IL-1 $\beta$ :** Interleukine-1  $\beta$

**IL-6:** Interleukin-6

**IR:** Insulin Resistance

**LPL:** Lipoproteinlipase

**MC4R:** Melanocortin 4 Receptor

**MCF-7:** Michigan cancer foundation -7

**NEFA:** Non Esterified Fatty Acids

**OL:** Olive Leaves

**OLE:** Olive Leaves Extract

**POD:** peroxidase

**POMC:** Pro-opiomelanocortin

**RAS:** Renin-Angiotensin System

**RBP-4:** Retinol Binding Protein-4

**SOCS-3:** Suppressor of Cytokine Signaling

**T2DM :** Type 2 Diabetes mellitus

**TG:** Triglycerides

**TNF $\alpha$  :** Tumor Necrosis Factor  $\alpha$

**Var:** Variety

**VLDL:** Very Low Density Lipoprotein

**WC:** Waist Circumference

**WHO:** World Health Organisation

**ZAG:** Zinc- $\alpha$ 2-glycoprotein

**TABLE OF CONTENTS**

<b>Introduction</b> .....	1
<b>1. Brief review on obesity</b>	
1.1. Obesity	
1.1.1. Definition.....	3
1.1.2. Epidimiologic of obesity.....	3
1.1.3. Classification of obesity.....	4
1.1.4. Physiopathology of obesity.....	5
1.1.5. Risk factors of obesity.....	7
1.1.6. Consequences and complications associated with obesity.....	8
1.1.7. Management and treatement of obesity .....	11
<b>2. Brief review on <i>Olea europaea</i> Variety: <i>Chemlali</i></b>	
2.1. Definition.....	14
2.2. Taxonomical clasification.....	14
2.3. Botanical description .....	15
2.4. Chemical composition.....	15
2.5. Benefits of <i>Olea europaea</i> leaves on human health.....	18
<b>3. Materiel and methods</b>	
3.1. Collection and preparation of the plant.....	21
3.2. Animal and diet.....	21
3.3. Experiment.....	21
3.4. Analytical procedures.....	22
3.4.1. Quantitative determination of Glucose.....	22
a. Test princip of glucose.....	22
b. Procedure.....	23
3.4.2. Quantitative determination of Triglyceride.....	23
a. Test princip of Triglyceride .....	23
b. Procedure.....	23
3.4.3. Quantitative determination of Cholesterol.....	24
a. Test princip of Cholesterol.....	24
b. Procedure.....	25
3.4.4. Quantitative determination of Albumine.....	25
a. Test princip of Albumin.....	25



## TABLE OF CONTENT

---

b. Procedure.....	25
3.4.5. Quantitative determination of Creatinine.....	25
a. Test princip of Creatinine .....	25
b. Procedure.....	26
4. <b>Results and discussion</b> .....	27
<b>Conclusion</b> .....	34

# **Introduction**

---

## INTRODUCTION

The olive tree (*Olea europaea*, *Oleaceae*) is a traditional symbol of abundance, glory, and peace. The olive fruit, its oil, and the leaves of the olive tree have a rich history of nutritional, medicinal, and ceremonial uses (Sedef *et al.*, 2009).

It is native to the Mediterranean and has been known for its medicinal properties since ancient times (Mosleh *et al.*, 2016). The olive tree lives and remains productive for thousands of years. It is the first botanical to have documented medicinal use (Lee-Huang, 2013), where The first mention of olive leaf's medicinal use in modern times was in 1843 when Daniel Hanbury of England reported a bitter substance from olive leaf tea was the agent responsible for healing malaria and associated fevers (Silva *et al.*, 2006).

The olive tree represents for Algeria the most important plant species regarding the area it occupies. Thus, Algeria has 20 million trees spread over an area of 207,822 ha. The mountainous regions of Kabylia are particularly recognized for the culture of the olive trees and the production of olive oil that is the principal fat used in their diets (Moussaoui *et al.*, 2010).

In recent years, much attention has been focused on using natural products as an alternative therapy for treatment of many diseases (Zoair, 2014), *Olea europaea* leaves have attracted growing interest in the scientific community. Hence, important scientific and technical efforts have been made to determine the value of this agricultural waste (Nashwa *et al.*, 2014).

Olive leaves (OL) are a source of many phytochemicals like phenolics and flavonoids compounds (Yateem, 2014), that are common plant secondary metabolites which have not only physiological functions in plants but also positive effects for human health because they can act as antioxidant (Mahmoudi *et al.*, 2015), anti-diabetic agents (Al-Okbi *et al.*, 2016), hypotensive, anti-atherosclerotic (Haloui *et al.*, 2010), it is used to enhance the immune system, as an anti-microbial (Dekanski *et al.*, 2009), anti-tumor and anti-inflammatory properties (Haloui *et al.*, 2010).

Obesity is an energy balance disorder in which energy intake exceeds energy expenditure (Shen *et al.*, 2014), resulting in fat accumulation (Ellulu *et al.*, 2014). That may have an adverse effect on health, leading to reduced life expectancy and/or increased health problems (Mohamed *et al.*, 2014). Obesity may cause a plethora of medical conditions such as diabetes (Luo *et al.*, 2012), hypertension, dyslipidemia (Jensen *et al.*, 2013), heart disease (Liao *et al.*, 2015).

Although the association of cardio vascular disease, hypertension, hyperlipidemia and diabetes with obesity suggests a possible role of OL in the regulation of serum lipids and obesity (**Peyrol *et al.*, 2017**). Taking all in consideration, it is of great interest to examine whether OL leads not only to Hypoglycemia but also reduces obesity.

This study was conducted to examine the effect of OL on serum lipids and body fat accumulation in rats. Here we describe that feeding 6.25% Olive leaves powder reduces body fat in rats.

# **Brief Review On Obesity**

## 1. Brief review on obesity

### 1.1. Obesity

#### 1.1.1. Definition


Obesity is an energy balance disorder in which energy intake exceeds energy expenditure (Shen *et al.*, 2013), resulting in fat accumulation (Ellulu *et al.*, 2014), that may have an adverse effect on health, leading to reduced life expectancy and/or increased health problems (Gamal *et al.*, 2014). It has been recognized as a disease by the World Health Organization (WHO) in 1997, since she became the first non-infectious disease in history. This is an epidemic that affects both industrialized countries those developing countries. It is a public health problem that affects all age groups and all professions (Karouche *et al.*, 2013).

Obesity is measured through the Body Mass Index (BMI), a simple index of weight–height relationship that indicates amount of body fat used to classify overweight and obesity in adults (Ellulu *et al.*, 2014).

#### 1.1.2. Epidemiology of obesity

In recent decades the prevalence of obesity and overweight has increased steadily in both developed and developing countries (Taleb *et al.*, 2012).

Obesity is a complex, multifactorial and largely preventable disease that, along with overweight, affects over one-third of the world's population today. By 2030 an estimated 38 % of the world's adult population will be overweight and another 20 % will be obese (Hruby, 2014). It has been estimated that there are approximately **1.9 billion** adults who are either overweight or obese (body mass index, BMI 25 kg/ m<sup>2</sup>). Among them, over **600 million** are obese (BMI30 kg/m<sup>2</sup>). According to WHO, this problem of energy imbalance may have contributed to an estimated **3.4 million** death each year including those resulted from cardiovascular disease, type 2 diabetes mellitus, and cancers (Chang *et al.*, 2017).



**Figure 1:** Prevalence of obesity, ages 18+, both sexes, 2014 (age-standardized estimates) source: WHO (**Romieu *et al.*, 2017**).

### 1.1.3. Classification of obesity

The two most common indexes in classifying obesity are: body mass index (BMI) and waist circumference (**Luo *et al.*, 2012**).

#### Body Mass Index (BMI)

Body mass index (BMI) is the most widely used method for the diagnosis of obesity and is correlated directly with the risk of comorbidities and mortality (**Liao *et al.*, 2017**). BMI is calculated by dividing a person's weight in kilograms by the square of their height in metres.

$$\text{Body weight (kg) / height (m)}^2$$

The calculation produces a figure that can be compared to various thresholds showed in **Table 1** for adults that define whether a person is underweight, of normal weight, overweight or obese.

**Table 1.** Cut points of BMI for the classification of obesity (**Kazan, 2015**).

BMI (kg /m <sup>2</sup> )	WHO classification	Popular description
<18 .5	Underweight	Thin
18.5-24.9	Normal range	"Healthy ", normal or "acceptable" weight
25.0-29.9	Grade 1 overweight	Overweight
30.0-39 .9	Grade 2 overweight	Obesity
≥40 .0	Grade 3 overweight	Morbidobesity

### Waist circumference

Waist circumference is commonly used as a surrogate measure for abdominal obesity (**Johansson, 2012**). The optimal level for measurement of waist circumference is midway from the lower rib margin to the anterior superior iliac crest, in the standing position.

**Table 2.** Waist circumference thresholds for abdominal obesity (**Johansson, 2012**).

Sex	Increased risk	High risk
Men	≥ 94 cm	≥ 102 cm
Women	≥ 80 cm	≥ 88 cm

Recent findings have indicated that WC is a stronger marker of health risk than is BMI (**Liao et al., 2017**).

#### 1.1.4. Physiopathology of obesity

Gastric distension via activation of vagal afferents is a signal for satiety, with gastric contractions signalling for hunger. Nutrients, neural impulses and hormones themselves act as afferent signals in the regulation of energy intake and expenditure (**Vassallo, 2007**). Uncontrolled expansion of fat cells leads to obesity and related diseases. The increase in adipocyte number is the result of recruitment of preadipocytes from pluripotent stem cells that reside in the vascular stroma of fat (adipose) tissue. The increase in adipocyte size is the result of increased fat accumulation (**Lee-Huang et al., 2013**).



Fat accounts for 21-37 % of the body weight of middleaged men and women. In case of obese individual more calories are consumed than expended and appetite does not subsequently reduced to compensate for the increase in energy stores (**Panigrahi et al., 2009**). With weight gain over time, excess lipids are distributed to many body compartments. Subcutaneous adipose tissue holds most of the stored lipid at a variety of anatomical sites (**Steven et al., 2017**). In addition to adipose tissue's main role in releasing fatty acids to be used as energy substrates, this tissue is an active endocrine organ, secreting several hormones and signaling substances with a number of biological functions (**Gambero et al., 2015**), called adipokines (**Kawashima et al., 2017**) such as: leptin, adiponectin, resistin, visfatin, apelin, retinol binding protein-4, vaspin, omentin, ZAG and proinflammatory cytokines (TNF $\alpha$ , IL-6) (**Leal et al., 2013**).

### **Exemples of adipokines function and obesity**

#### **Leptin**

Leptin is a peptide hormone produced (**Abdalla, 2017**), by adipocytes (**Vassallo, 2007**), implicated in the regulation of appetite (**Santi-Cano, 2014**). It acts to reduce food intake and is believed to increase sympathetic nervous system activity (**Vassallo, 2007**). Thus, a deficiency in leptin signaling either via leptin deficiency or leptin resistance leads to overfeeding and may account for some genetic and acquired form obesity (**Gamal et al., 2014**).

#### **Adiponictin**

Adiponectin is the most abundant circulating peptide hormone (**Chun-Laam et al., 2017**), it is almost exclusively synthesized by adipocytes and is present at high levels (3 to 30  $\mu\text{g ml}$ ) in the blood.

The beneficial effects of adiponectin on insulin sensitivity seem to be mediated in part by its ability to activate AMP-activated protein kinase (AMPK) in skeletal muscle and liver, because AMPK activation leads to an increase in fatty acid oxidation and glucose uptake in muscle tissue, and inhibition of gluconeogenesis in the liver. Adiponectin expression was found to be decreased in obesity (**Ouchi, 2011**).

### Pro-inflammatory cytokines

Adipose tissue is mainly comprised of adipocytes, although other cell types contribute to its growth and function, including pre-adipocytes, lymphocytes, macrophages, fibroblasts and vascular cells (Ouchi, 2011).

Obesity is accompanied by increases in macrophages and other immune cells in adipose tissue, in part because of tissue remodeling in response to adipocyte apoptosis. These immune cells secrete proinflammatory cytokines (TNF $\alpha$ ), which contribute to the insulin resistance that is often present in patients with obesity (Steven *et al.*, 2017).

**Table3.** Adipokines profile in obesity (Leal *et al.*, 2013).

Adipokine	Main function	Obesity
	<b>Energy homeostasis</b>	
Leptin	Beneficial: $\uparrow$ energy expenditure and $\uparrow$ energy consumption	$\uparrow$ but there is neuronal resistance to its action
ZAG	Beneficial : $\uparrow$ energy expenditure and $\uparrow$ lipolysis	$\downarrow$
	<b>Glucose homeostasis</b>	
Adiponectin	Beneficial : $\uparrow$ AMPK and $\downarrow$ gluconeogenesis	$\downarrow$
Vaspin	Beneficial : $\uparrow$ insulin sensitivity $\downarrow$ food intake	$\uparrow$ as a compensatory role in metabolic complications associated with obesity
Omentin	Beneficial : $\uparrow$ adipocytes glucose uptake	$\downarrow$
Visfatin	Beneficial : $\uparrow$ insulin secretion	$\uparrow$ but controversial- it is a compensatory response to
Leptin	Harmful : $\uparrow$ SOCS-3 expression	IR
Resistin	Harmful : $\uparrow$ gluconeogenesis and $\downarrow$ AMPK and	$\uparrow$
RBP-4	IRS-2	$\uparrow$
	Harmful : $\uparrow$ hepatic gluconeogenesis and $\downarrow$	$\uparrow$
TNF- $\alpha$	muscle insulin signaling	$\uparrow$
IL-6	Harmful : $\downarrow$ insulin signaling	$\uparrow$
	Harmful : $\downarrow$ insulin signaling	$\uparrow$

#### 1.1.5. Risk factors of obesity

Like any other multifactorial diseases, obesity is a complex disease (Alamukii *et al.*, 2017), interplaying of both genetic and environmental factors (Perry, 2015). The causes of obesity are varied and complex (Scott *et al.*, 2017), involving social, biological and

psychosocial factors, A sedentary lifestyle and a high-calorie diet seem to be the most important factors in the development of obesity (**Gamboero *et al.*, 2015**).

#### **1.1.5.1. Modifiable factors**

- **Environment**

factor that has been suggested as being obesogenic is a high energy density of foods (i.e., an energy content of more than about 225–275 kcal per 100 g) (**Romieu *et al.*, 2017**), such as those present in «fast food» (**Rodríguez-Martín *et al.*, 2009**), palatable foods that are often served in large portions; decreasing time spent in occupational physical activities and displacement of leisure-time physical activities with sedentary activities such as television watching and use of electronic devices (**Steven *et al.*, 2017**) such as computer usage, transport mode (**Duncan *et al.*, 2011**); Medications used for the management of conditions other than obesity can contribute to or exacerbate weight gain in susceptible individuals (**Apovian *et al.*, 2015**).

#### **1.1.5.2. Non modifiable factors :**

- **Genetic factors**

Like many other medical conditions, obesity is the result of interplay between genetic and environmental factors. Polymorphisms in various genes controlling appetite and metabolism predispose to obesity when sufficient food energy is present (**Gamal *et al.*, 2014**). The marked differences in adiposity between individuals seem to be explained mainly by our genes (**Gummesson, 2009**). Common for most of these genes is their involvement in hypothalamic regulation of food intake, including the leptin gene, the pro-opiomelanocortin (POMC) gene, and the melanocortin 4 receptor gene (MC4R) (**Pepper *et al.*, 2010**). Individuals with mutations in these genes typically present with an increased drive to eat and early-onset obesity (**Gummesson, 2009**).

#### **1.1.6. Consequences and complications associated with obesity**

Adipose tissues can influence and communicate with many other organs, including the brain, heart, vasculature, liver and muscle, through the production of various secretory factors or adipokines (**Ouchi *et al.*, 2011**). Obesity is a multifactorial and complex disorder (**Vassallo, 2007**), as a result of dysregulated expression of these factors, caused by excess adiposity and adipocyte dysfunction, has been linked to the pathogenesis of various disease

processes (**Ouchi *et al.*, 2011**). It has an adverse effect on health (**Luo *et al.*, 2012**), that, associated with a shorter life expectancy (**Abdalla, 2017**).

Obesity may cause a plethora of medical conditions such as diabetes (**Luo *et al.*, 2012**), hypertension, dyslipidemia (**Jensen *et al.*, 2013**), heart disease (**Liao *et al.*, 2015**).

#### **1.1.6.1. Diabetes mellitus (T2DM)**

In particular, T2DM defined together with obesity (Diabesity) as the XXI Century epidemic (**Liguri *et al.*, 2017**).


Obesity is the main driver for the current epidemic of Type 2 diabetes (T2D). As weight increases, there is increasing insulin resistance. This means that the pancreas has to make more insulin in order to maintain normal blood glucose levels. Fat tissue not only increases the demand for insulin, it also secretes toxins that cause the insulin secreting beta-cells to fail. T2D can occur at any BMI, but there is a sharp increase in risk of T2D when BMI exceeds 30 kg/m<sup>2</sup> (**Price *et al.*, 2015**).

#### **1.1.6.2. Hypertention**

Hypertension is probably the most common comorbidity associated with obesity (**Scott *et al.*, 2017**). The renin-angiotensin system (RAS) is well recognized for its key role in regulation of blood pressure, fluid homeostasis, vasoconstriction, hormone secretion, kidney function, and cellular growth. Angiotensin is overexpressed in obesity, directly contributing to obesity-related hypertension. This hyperkinetic state is supplanted by increasing evidence of systolic and diastolic myocardial dysfunction, which may progress to overt clinical heart failure (**Rowland, 2007**).

#### **1.1.6.3. Dyslipidimia**

Obesity and dyslipidemia are strongly associated with each other (**Tanveer *et al.*, 2017**). Obesity is the most common cause of dislipidemia (**Gamal *et al.*, 2014**). It is characterized by impaired adipocytes trapping of fatty acids and excessive adipocytes lipolysis. These alterations lead to high circulating non esterified fatty acids (NEFA) levels that result in increased hepatic lipogenesis. Overwhelming of hepatic secretory capacity leads to hepatic steatosis by the newly synthesized triglycerides (TG) and increased VLDL circulating levels. An impaired lipoprotein lipase activity and enhanced cholesteryl ester transfer protein (CETP) - mediated lipid exchanged contribute to the observed HDL-C reduction in obesity (**Santi-Cano, 2014**).



**Figure 2.** The relationship between obesity and dyslipidemia (Liguri *et al.*, 2017).

#### 1.1.6.4. Cardiac alteration

The link between obesity and cardiovascular disease is believed to be through a number of metabolic pathways and their complications such as atherogenic dyslipidemia, elevated blood pressure, and elevated plasma glucose (Rowland, 2007).

#### 1.1.6.5. Cancer

Epidemiological studies have shown that obesity is associated with increased risk of many cancer types (Xie *et al.*, 2016), including colorectum, endometrium, kidney, oesophagus, postmenopausal breast, pancreas, gastric cardia, liver, ovary, thyroid, meningioma, multiple myeloma, and advanced prostate cancers (Romieu *et al.*, 2017).

The relations between obesity and cancer can be explained by variations in the metabolism of endogenous hormones (contain of insulin, insulin like growth factors and sex steroids) which may cause impairment of the normal balance between cell proliferation differentiation and apoptosis (Kazan, 2015). Secrete multiple biologically active polypeptides that act by endocrine, paracrine, and autocrine mechanisms (Robert, 2009). Different assumed biological mechanisms consisting of changes in the bioavailability and synthesis of sex steroid hormones, insulin resistance, release of growth factors and/or pro-inflammatory cytokines and deviant energy disposal and expenditure can cause progression and genesis of cancer. In addition that, cancer genesis can indirectly be contributed to through a progressive

aggregation of environmental chemical carcinogens in the adipose tissue by a modification of the hormonal milieu (**Kazan, 2015**).

#### **1.1.6.6. Neurological disorders**

Psychological damage caused by overweight and obesity ranges from lowered self-esteem to frank clinical depression. Indeed, rates of anxiety and depression are three to four times higher among obese individuals. Obesity significantly increases the risk of Alzheimer's disease. A strong correlation exists between BMI and high levels of amyloid, i.e. the protein that accumulates in the Alzheimer's brain, destroying nerve cells and producing cognitive and behavioral problems (**Gamal *et al.*, 2014**).

#### **1.1.7. Management and Treatment of obesity**

Obesity is a chronic condition that is difficult to treat (**Gummesson, 2009**). The potencies of treatment options for the management of obesity including behavior/lifestyle interventions, pharmacotherapy, and bariatric surgery (**Patel, 2015**).

We recommend that diet, exercise, and behavioral modification be included in all obesity management approaches for body mass index (BMI) 25 kg/m<sup>2</sup> and that other tools such as pharmacotherapy (BMI 27 kg/m<sup>2</sup> with comorbidity or BMI over 30 kg/m<sup>2</sup>) and bariatric-surgery (BMI 35 kg/m<sup>2</sup> with comorbidity or BMI over 40 kg/m<sup>2</sup>) be used as adjuncts to behavioral modification (**Apovian *et al.*, 2015**).

##### **1.1.7.1. Lifestyle Intervention**

Current guidelines suggest the use of comprehensive lifestyle modification as the first-line treatment for obesity. Lifestyle interventions designed to modify eating behaviors and physical activity are the first option for weight management (**Steven, 2017**), Being physically active and following a healthy diet have been shown to reduce the risk of premature death or morbidity (**Kahlert, 2015**).

##### **1.1.7.2. Pharmacotherapy**

Most of the currently available pharmacological treatments of obesity reduce food intake or decrease the efficiency of food absorption in the intestines (**Chabowska-Kita *et al.*, 2016**). There are two broad categories into which current anti-obesity agents can be divided. Centrally acting drugs modulate signaling pathways in the central nervous system (CNS) and

thus suppress appetite. Peripherally acting agents promote weight loss by reducing the absorption of nutrients (Majanović *et al.*, 2016).

### **a. appetite Suppressants drugs**

#### **a.1. Amphetamines**

In the 1940s and 1950s, amphetamines became the primary drugs for obesity treatment. Amphetamines act on hypothalamic receptors to release norepinephrine and, to a lesser extent, dopamine and serotonin, increasing central nervous system (CNS) activity and resting energy expenditure, and decreasing appetite and food intake, thus leading to weight reduction (Haslam, 2016).

#### **a.2. Phentermine**

Phentermine is a centrally acting sympathomimetic agent, which mainly acts to increase norepinephrine in the CNS, thereby suppressing appetite (Majanović *et al.*, 2016).

#### **a.3. Sibutramine**

sibutramine acts as a sympathomimetic, blocking neuronal uptake of any released serotonin and norepinephrine, thereby prolonging stimulation of peripheral beta-adrenergic receptors to induce satiety (Haslam, 2016).

### **b. Lipase Inhibitors**

#### **b.1. Orlistat**

Orlistat is a reversible inhibitor of pancreatic lipase (Majanović *et al.*, 2016), prevent the digestion and absorption of some dietary fats (Paul *et al.*, 2004) from the gut. At the standard prescription dose of 120 mg three times daily before meals, orlistat prevents approximately 30% of dietary fat from being absorbed, there by reducing caloric intake (Majanović *et al.*, 2016).

#### **1.1.7.3. Bariatric surgery**

One of the most successful interventions in extreme obesity is bariatric surgery (Tehmina *et al.*, 2016). Bariatric surgery is indicated in obese subjects who have been unable to lose weight through lifestyle change alone (Johansson, 2012). Bariatric / Metabolic

surgery (BMS) is the only form of treatment for severe obesity that provides significant long-term weight loss and maintenance (**Tehmina et al., 2016**).

Bariatric surgery includes procedures that act by either reducing stomach size or capacity or by passing part of the intestine or a combination of the two. Although the surgical restriction in the size of the stomach was initially assumed to be a major factor in resultant weight loss (**Tehmina et al., 2016**).

#### **1.1.7.4. Nutritional intervention**

- **Vegetables and fruits(F&V)**

Vegetables and fruits are considered in dietary guidance because of their high concentrations of dietary fiber, vitamins, minerals, especially electrolytes; and more recently phytochemicals, especially antioxidants. Interestingly, phytochemicals in F&V have been found to act as anti-obesity agents because they may play a role in suppressing growth of adipose tissue . Adiposity is closely related to biomarkers of oxidative stress and inflammation and a diet rich in F&V can modify these adiposity related metabolic biomarkers in overweight women (**Pem et al., 2015**).



**Brief Review on *Olea*  
*europaea***

## 2. Brief review on *Olea europaea* variety: *Chemlali*

### 2.1. Definition

*Olea europaea* is a typical fruit-tree widely cultivated in the Mediterranean area, belonging to Oleaceae family, even that its cultivation has been extended to many of the region of the world (Dekdouk et al., 2015).



Figure 3. *Olea europaea* tree variety *Chemlali* (Khedara, Athamna , Benouchenne., 2017)

### 2.2. Taxonomical classification of *Olea europaea* var: *Chemlali* (Chiappetta et al., 2012).

**Kingdom:** *Plantae*

**Phylum:** *Magnoliophyta*

**Class:** *Rosopsida*

**Order:** *Lamiales*

**Family:** *Oleaceae*

**Sub-family:** *Oleideae*

**Genus:** *Olea*

**Species:** *europaea*

**Variety:** *Chemlali*

### 2.3. Botanical description

The olive tree, botanically classified as *Olea europaea* is one of the most important fruit trees (Afaneh *et al.*, 2015). Olive is a shrub with permanent green leaves (Moghaddam *et al.*, 2013), in the family Oleaceae, native to the coastal areas of the Mediterranean region (Al-Okbi *et al.*, 2016). The climate is characterized by warm weather and extended sunlight irradiation (Erbey *et al.*, 2010). It grows to approximately 6-9 metre in height. Leaves are 7.5 cm long, narrow opposite, lanceolate or linear, with entire margins and acute tips, silver-green (grey green) on top, the underside lighter, containing fine white. The leaves are gathered throughout the year (HMPC, 2011).



**Figure 4:** *Olea europaea* variety *Chemlali* leaves

### 2.4. Chemical composition of *Olea europaea* variety: *chemlali*

The chemical composition of olive leaves varies depending on several conditions such as origin, proportion of branches on the tree (Sedif *et al.*, 2009), storage conditions, weather conditions, moisture content, and degree of soil contamination (Vogel *et al.*, 2015).











Olive leaves can be considered as a potential source of bioactive compounds. Numerous studies have been focused on the composition of olive leaves based on phenolic compounds considering their richness of such valuable compounds (Abaza *et al.*, 2015).

- **Phenolic compound**

The olive leaves contain phenolic compounds; the oleuropein, hydroxytyrosol, verbascoside, apigenin-7-glucoside and luteolin-7-glucoside are the most abundant already identified in olive leaf extracts (**Vogel et al., 2015**).

Oleuropein is the major phenolic and the active constituent of olive (*Olea europaea*) leaf (**Al-Azzawie et al., 2006, Afaneh et al., 2015**), Olive leaves have the highest amount of oleuropein whereas content in olive oil ranges between 0.005% and 0.12% while that in olive leaves ranges between 1% and 14%. Studies have shown that oleuropein possesses a wide range of pharmacologic and health promoting properties including, antihyperglycaemic, immune-stimulant, cardioprotective, hypotensive, and anti-inflammatory effects (**Al-Azzawie et al., 2006**).

**Table 4.** The polyphenol compounds present in olive leaves

Group	Compound	Chemical formula
secoiroids <sup>1</sup>	Oleuropein <sup>1</sup>	
	Hydroxytyrosol <sup>2</sup>	
Flavonoids <sup>3</sup>	Luteolin-7-O-glucoside	
	Apigenin-7-glucoside <sup>4</sup>	
	Quercetin <sup>5</sup>	
Substituted phenols <sup>6</sup>	Tyrosol <sup>6</sup>	
	Vanilic acid <sup>7</sup>	
	Caffeic acid <sup>7</sup>	
Cinnamic acid derivatives <sup>6</sup>	Verbascoside	
Triterpene <sup>8</sup>	Oleanolic acid	

<sup>1</sup> Qadir *et al.*, 2016; <sup>2</sup> Erbay *et al.*, 2010; <sup>3</sup> Benavente *et al.*, 2000; <sup>4</sup> Omar, 2010; <sup>5</sup> Olayinka *et al.*, 2015 ; <sup>6</sup> Abaza *et al.*, 2015; <sup>7</sup> Kawsar *et al.*, 2008; <sup>8</sup> Alhamd *et al.*, 2015.

- **Fatty acids**

The polyunsaturated fatty acids including the omega-3 and omega-6 families detected in the plants constitute an important class of phytochemicals due to their generalized beneficial health effects (**Guimaraes et al., 2009**).

The fatty acid composition of OL is shown in **Table5**. The percentage of polyunsaturated fatty acids in OL of *Chamlali* variety was higher than that of saturated fatty acids and the major fatty acids found were linolenic acid (**Bahloul et al., 2014**).

**Table 5.** Fatty acids composition in OL of Chamlali variety (**Bahloul et al., 2014**).

Fatty acid	Percentage (%)
Linolenic acid ( $\omega_3$ )	30.02
Oleic acid ( $\omega_9$ )	26.36
Linoleic acid ( $\omega_6$ )	14.48
Polyunsaturated fatty acids	44.50
Saturated fatty acids	28.99

- **Fibers**

The greatest proportion of hemicellulose fibers are arabionosa type, whereas the branches have predominantly mannose (**Vogel et al., 2015**).

- **Minerals**

**Table7.** Mineral composition of olive leaves Variety *Chamlali* (**Bahloul et al., 2014**).

Minerals	Amount (mg·g <sup>-1</sup> dry matter)
Calcium	10.39
Potassium	7.87
Magnesium	1.50
Sodium	0.82

#### 2.4. Benefits of *Olea europaea* L leaves on human health

Olive leaves have had a lot of medicinal applications in traditional and modern medicine (**Mosleh et al., 2016**), both the oil and the dried green-grayish colored leaves are used medicinally (**Afaneh et al., 2015**). This plant has been mentioned in traditional medicine as having the following effects (**Moghaddam et al., 2013**), anti-diabetic agents (**Al-Okbi et**

*al.*, 2016), hypotensive, anti-atherosclerotic (Haloui *et al.*, 2010), it is used to enhance the immune system, as an anti-microbial and in heart disease (Dekanski *et al.*, 2009), anti-tumor and anti-inflammatory properties (Haloui *et al.*, 2010), Olive leaf extract was shown to have therapeutic role towards nephrotoxicity, and attenuates obesity in mice (Shen *et al.*, 2014).

#### 2.4.1. Anti-oxidant effect

It is known that free radicals cause oxidative stress and therefore they can provoke damaging of DNA molecules, proteins and lipids in biological systems (Vogel *et al.*, 2014), leading to different diseases as atherosclerosis, rheumatoid arthritis and inflammatory bowel diseases (yancheva *et al.*, 2016). Leaves extract had antioxidant activity higher than vitamin C and vitamin E, due to the synergy between flavonoids, oleuropeosides and substituted phenols (Talal *et al.*, 2011). Many reports indicate that olive leaves contain significant amounts of oleuropein and phenols (Mourtzinis *et al.*, 2007; Lee *et al.*, 2009; Abaza *et al.*, 2011). Oleuropein have been reported as a good antioxidant in vitro through chelating of Cu and Fe metallic ions which then catalyse free radical formation and in vivo through the inhibition of enzymatic oxidation such as lipoxygenases (Qadir *et al.*, 2016).

#### 2.4.2. Anti diabetic effect

Olive-tree leaves are well known as a traditional antidiabetic and antihypertensive herbal drug (Sedef *et al.*, 2009). Oleuropein reported to have an antihyperglycaemic effect in diabetic rats (Al-Azzawie *et al.*, 2006). It acts as ROS suppresser and  $\beta$  cell protector in alloxan-induced diabetic rats (Qadir *et al.*, 2016). Administration of Olive leaves extract (OLE) reduced significantly the blood glucose levels. Hypoglycemic activity of OLE may result from two mechanisms: increasing peripheral uptake of glucose (Laaboudi *et al.*, 2016) and it may also stimulate the release of insulin. Furthermore OLE was found to inhibit the activities of  $\alpha$ -amylases from human saliva and pancreas. In Animal models studies the hypoglycemic effect of OLE may be facilitated through the reduction of starch digestion and absorption (Mousa *et al.*, 2014). Moreover oleuropein in olive leaves is reported to act as a-glucosidase inhibitor, reducing the absorption of carbohydrates in the gut (Wainstein *et al.*, 2012).

#### 2.4.3. Anti-hypertensive effects

Some indications of olive leaf in traditional medicine are the prevention and treatment of hypertension (Mosleh *et al.*, 2016). The antihypertensive action of olive leaf extract has been shown in several studies (Vogel *et al.*, 2015).

The majority of the human evidence involves the use of olive leaf to reduce blood pressure (BP). It has been postulated that oleuropein reduces BP via blockade of L-type calcium channels and verbascoside via inhibition of angiotensin converting enzyme (MacFarlane, 2016).

#### 2.4.4. Anti microbial effects

Both Oleuropein and hydroxytyrosol showed antimicrobial activity (*Bacillus subtilis*, *B. cereus*, *Staphylococcus aureus*, *Salmonella typhi*, *Vibrio cholerae*, *V. parahemolyticus* and *Micrococcus* sp.) (Sabry, 2014). The Olive leaves extract inhibitant-viral activities against several types virus like *haemorrhagic septicaemia rhabdovirus* (Alhamd *et al.*, 2015).

OLE may have a role in regulating the composition of the gastric flora by selectively reducing levels of *Helicobacter pylori* and *Campylobacter jejuni* (Mosleh *et al.*, 2016).

#### 2.4.5. Cardioprotective effects

The phenolic compounds of olive leaves and olive oils in the Mediterranean diet have been associated with a reduced incidence of heart disease (Sedef *et al.*, 2009). Oleuropein, the main constituent of olive leaves extract, protects membrane from lipids oxidation, causes dilatation of coronary blood vessels (Sabry, 2014).

Hydroxytyrosol provides resistance to oxidation, and also it exhibited a range of pharmacological properties beneficial for the cardiovascular system. These actions included enhanced nitric oxide production, decreased blood pressure, inhibition of platelet aggregation (Satya *et al.*, 2013).

#### 2.4.6. Effects of olive leaf in chronic colitis

The effect of oleuropein administration in patients with chronic colitis was tested by Giner and collaborators, in a study that evaluated the effects of a diet supplemented with oleuropein, equivalent to 500mg/kg of body weight for 56 days in mice with chronic colitis induced by dextran sulfate sodium (Vogel *et al.*, 2015). In the group with the diet supplemented with oleuropein decreased the release of inflammatory cytokines such as interleukin-6 (IL-6) and interleukin-1 $\beta$  (IL-1 $\beta$ ). The IL-6 is a pro-inflammatory cytokine that



plays an important role in the development of inflammatory intestinal diseases (**Vogel *et al.*, 2015**).

#### **2.4.7. Anti-cancer effect**

Phenolic components, which have a role in cancer prevention are rich in olive leaf (**Mosleh *et al.*, 2016**), among them Oleuropein, which is completely nontoxic in several animal species, has antitumoral activity (**Sedef *et al.*, 2009**). Hydroxytyrosol rich extract from olive leaves has *in vitro* anti-tumoral activities and modulates cell cycle progression in MCF-7 human breast cancer cells. Therefore the OLE will be investigated for its probable use as an anticancer food additive (**Mosleh *et al.*, 2016**).

# **Material And Methods**

### 3. MATERIALS AND METHODS

#### 3.1. Collection and preparation of the plant

*Olea europaea* leaves (OL), variety: *chemlali* were collected from Agrolival's farm at Wed El Ndjaa, Mila. OL were dried under shade for 13 days then powdered with electric grinder (COBRA, Algeria).



**Figure 3.** *Olea europaea* tree variety *Chemlali*



**Figure 4:** *Olea europaea* variety *Chemlali* leaves

#### 3.2. Animals and diets

Males and females *Albinos Wistar* rats, were obtained from animal house (Animal Biology Department, Constantine University 1), weighing 67-236g were used. Rats were individually housed in plastic cages. Room temperature was kept at 24 C° on a 12 h light-dark cycle (lights on, 08:00-20:00 h). All rats were given free access to water and experimental diets. Rats were fed, in a two-ways design, diets with or without containing olive leaves powder (OLP). Composition of the basal diet is listed in Table 1. OLP was added to the basal diet at the level of 6.25%. This level of dietary OLP has been reported that OL has a hypoglycemic effect in diabetic rats (**Moghaddam et al., 2013**). Supplementation of OLP was made at the expense of corn starch. All animals were fed the same amount of experimental diets (12 g d1-5, 14g d6-11, 16g d12, 18g d13 and 20g for d14-35). All the diets were daily incorporated into the food cups in the cages at 11:00h and all rats completely consumed the diets until the next morning. After 5 weeks of consuming diets (5 animals per group), food was removed from the cages at 07:30 h and the rats were anesthetized with chloroform and killed between 11:00 h and 14:00 h. Blood was collected by heart puncture using portal vein prelevement and samples were allowed to clot on ice. Serum samples were obtained by centrifugation (3000 rpm for 20 min). Abdominal adipose tissues (Epididymal and perirenal adipose tissues) and liver were immediately removed, weighed and stored at -20 C° until use.

### 3.3. Experiment

Rats were divided into two groups of 5 rats for each group, control group (C) and olive leaves powder diet group (OLP).

**Table 9.** Composition of basal diets

	Control group (C)	Olive leaves powder group (OLP)
	(% W/W)	
D-Methionine	0.1	0.1
Vitamins mixture <sup>1</sup>	1	1
Salt mixture <sup>1</sup>	3.5	3.5
Casein	20	20
Corn oil	5	5
Sucrose	21.7	21.7
Cellulose powder	5	5
Corn starch	43.5	37.25
Powdered olive leaves	0	<b>6.25</b>

<sup>1</sup>Diets are modified version of AIN J. Nutr. 107: 1340-1348 (1977).


### 3.4. Analytical procedures

Serum concentrations of creatinine and glucose were measured by kits (**CYPRESS DIAGNOSTICS**), Triglycerides are measured by kits (**SPINREACT**), total cholesterol and albumine were measured using automate (**COBAS INTEGRA 400 plus**, laboratory of biochemistry, Melitary Hospital, Constantine).

#### 3.4.1. Quantitative determination of Glucose

##### a. Test principle of Glucose

A colorimetric assay following two coupled enzymatic reactions. A specific enzymatic reaction, in which glucose oxidase (GOD) oxidizes glucose present in the sample to gluconic acid and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) that serves as the substrate for the peroxidase (POD) in a coupled reaction and it is detected by a chromogenic oxygen acceptor (phenol, 4-aminophenazone (4-AP)) resulting a colored product.



The intensity of the color is proportional to the glucose concentration (**Kaplan *et al.*, 1984**).

### b. Procedure



One milliliter of the reaction mixture containing 92 mM TRIS buffer (pH 7.4), 0.3 mM phenol, 15000 U/L glucose oxidase (GOD), 1000U/L peroxydase (POD) and 2.6 mM 4-aminophenazone (4-AP) was incubated with 10  $\mu$ l sample. After incubation at 37°C for 10 Min., optical density of sample and standard (Glucose aqueous primary standard 100 mg/dl) were recorded against blank. At the wavelength 505nm using Spectrophotometer (Ultrospec 2100 *pro*).


The concentration of serum glucose was shown directly on Spectrophotometer's screen.

### 3.4.2. Quantitative determination of Triglycerides

#### a. Test principle of Triglycerides

Sample triglycerides incubated with lipoproteinlipase (LPL), liberate glycerol and free fatty acids. Glycerol is converted to glycerol-3-phosphate (G3P) and adenosine-5-diphosphate (ADP) by glycerol kinase and ATP. Glycerol-3-phosphate (G3P) is then converted by (GPO) to dihydroxyacetone phosphate (DAP) and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>). In the last reaction, hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) reacts with 4-aminophenazone (4-AP) and p-chlorophenol in presence of peroxidase (POD) to give a red colored dye:





The intensity of the color formed is proportional to the triglycerides concentration in the sample (Buccolo G *et al.*, 1973; Kaplan A *et al.*, 1984).

### b. Procedure

One milliliter of working reagent contain 50 mM GOOD buffer (pH 6,3), 2 mM p-chlorophenol, 150000 U/L of LPL, 500 U/L of GK, 3500 U/L of GPO, 440 U/L of POD, 0.1 mM 4-AP and 0.1 mM of ATP was incubated with 10  $\mu\text{l}$  sample. After incubation at 37°C for 5 min, optical density of sample and aqueous primary standard (TRIGLYCERIDE CAL 200mg/dL) were recorded against blank. At the wavelength 505nm using Spectrophotometer (Ultrospec 2100 *pro*).

The concentration of serum triglycerides was calculated by the difference in absorbance between the standard and the sample.


$(\text{Abs}) \text{ Sample} / (\text{Abs}) \text{ Standard} * 200 (\text{Standard conc}) = \text{mg/dl triglycerides in the sample}$

Then  $\text{mg/dl} * 0.0113 (\text{conversion factor}) = \text{mmol/L}$ .

### 3.4.3. Quantitative determination of total Cholesterol

#### a. Test principle of Cholesterol

The cholesterol is determined after enzymatic hydrolysis and oxidation. The quinoneimine indicator is formed by the hydrogen peroxide and 4-aminoantipyrine in the presence of phenol and peroxidase, according to the following reactions:



The intensity of the color formed is proportional to the cholesterol concentration in the sample (Naito *et al.*, 1984; Meittini *et al.*, 1978).

#### b. Procedure

One milliliter of the reaction mixture containing 90 mM PIPES buffer (pH 6.9), 26 mM phenol, 1000 U/L Cholesterol esterase (CHE), 300U/L Cholesterol oxidase (CHOD), 650 U/L Peroxidase (POD) and 0.4 mM 4 – Aminophenazone (4-AP) was incubated with 10 µl sample. Each sample had both blank and standard (Cholesterol aqueous primary standard 200 mg/dl). After incubation at 37°C for 10 min, optical density at the wavelength 505 nm was recorded using Spectrophotometer (MINDRAY. BA-88A). The concentration of serum cholesterol was calculated from the difference in absorbance between the standard and the sample.

$(A) \text{ Sample} / (A) \text{ Standard} \times 200 \text{ (Standard conc.)} = \text{mg/dl cholesterol in the sample. Then}$   
 $\text{mg/dl} \times 0.0258 \text{ (conversion factor)} = \text{mMol/L}$

### 3.4.4. Quantitative determination of Albumine

#### a. Test principle of Albumine

Albumin in the presence of Bromcresol green at a slightly acid pH, produces a colour change of the indicator from yellow-green to green-blue. The intensity of the color formed is proportional to the albumin concentration in the sample.

#### b. Procedure

One milliliter of the reaction mixture containing 0.12 mM Bromcresol green buffer (pH 4.2) was incubated with 5 µl sample. Each sample had both blank and standard (Albumin aqueous primary standard 5 g/dl). After incubation for 10 min at room temperature (15-25 °C) optical density at the wavelength 630 nm was recorded using Spectrophotometer (MINDRAY. BA-88A). The concentration of serum albumin was calculated from the difference in absorbance between the standard and the sample.

$(A) \text{ Sample} / (A) \text{ Standard} \times 5 \text{ (Standard conc.)} = \text{g/dl albumin in the sample. Then g/dl} \times$   
 $144.9 = \mu\text{mol/L.}$

### 3.4.5. Quantitative determination of Creatinine

#### a. Test principle of Creatinine

The assay is based on the reaction of creatinine with sodium picrate, as described by Jaffé. Creatinine reacts with alkaline picrate forming a red complex (Janovsky complex). The

time interval chosen for measurements avoids interferences from other serum constituents (absorbance at 500 nm).

The intensity of the color formed is proportional to the creatinine concentration in the sample (**Kaplan *et al.*, 1984**).

**b. Procedure**

Creatinine alkaline Reagent containing 0.29 mol/L sodium hydroxide and Creatinine Picrate Reagent containing 25 mM/L picric acid. A working reagent prepared by mixing one volume of creatinine picrate reagent (500µl) and one volume of creatinine alkaline reagent (500µl) directly in spectrophotometer's cuvettes then, 100µl sample was added and mixed well with micropipette.

Analyser calculated automatically serum creatinine concentration.

**2.4. Statistical analysis**

All results were tested for statistical significance by Student's t-test using StatView software.




# **Results And Discussion**


#### 4. Results and discussion

- **The effect of 6.25% of *Olea europaea* leaves powder (*Chemlali*) (OLP) on final and gain body weight**

There was no significant difference on final and gain body weight between the two groups (**Fig 5, 6**). Study by **Shen *et al* (2014)** indicated a trend of lower final and gain body weight in mice by olives extract supplementation to control group for 8 weeks. The no influence of feeding OLP for 5 weeks found in our results, suggesting that the final and gain body weight are mediated through a mechanism involving feeding period and the concentration of the active compounds of OLP.




Value are means  $\pm$  SE (n= 5) for each group




Value are means  $\pm$  SE (n= 5) for each group

- **Effect of 6.25% of OLP on Relative Liver and Kidney Weight**

There was no significant difference in relative liver and kidney weight between the two groups (**Fig 7, 8**).



Value are means  $\pm$  SE (n= 5) for each group




Value are means  $\pm$  SE (n= 5) for each group

- **Effect of 6.25% OLP on serum Glucose**

There was no significant difference in serum glucose between the two groups (**Fig 9**). Feeding rats olive leaves extract for 8 weeks significantly lower serum glucose concentration (**Moghaddam *et al.*, 2013; Shen *et al.*, 2014**).


This difference in our results may be due to the feeding period and the other active compounds present in OLP.



Value are means  $\pm$  SE (n= 5) for each group

- **Effect of 6.25% OLP on total cholesterol**


There was no significant difference in serum total cholesterol between the two groups (**Fig 10**). Olive leaves extract is well known to induce hypocholesterolemia (**Moghaddam *et al.*, 2013; Shen *et al.*, 2014; Al-Attar and Shawush, 2014**). The unchanged results found in our study are might due the feeding period and the other active compound in OLP.



Value are means  $\pm$  SE (n= 5) for each group

- **Effect of 6.25% OLP on serum Triglycerides**

This study showed that feeding rats 6.25% of OLP significantly decreased serum TG (32.60%,  $P < 0, 05$ ) (**Fig 11**). Our results are in agreement with the previous studies (**Alzzawi *et al.*, 2004; Moghaddam *et al.*, 2013; Shen *et al.*, 2014**). The lower concentrations of TG might achieved by two mechanisms either by reducing plasma level of FFA that submitted to beta oxidation, the lower content of FFA, which flows into the liver through, may cause less triglyceride synthesis in the liver (**Shen *et al.*, 2014**) or by augmentation of hydrolysis of TG to FFA by lipase in the liver.




Value are means  $\pm$  SE (n= 5) for each group

\*Significantly different from control ( $P < 0.05$ ).


- **Effect of 6.25% OLP on Epididymal and Perirenal adipose tissue weight**

Dietary 6.25% of OLP caused 37% and 45% reduction in epididymal and perirenal adipose tissue weight respectively (**Fig 22, 13**). Hydroxytyrosol (metabolite of oleuropein) has been known to reduce both of epididymal and perirenal fat formation (**Perol *et al.*, 2017**). In view of this fact, we suggest that the anti-obesity effect of OLP might be at least in part accounted by a common mechanism involving OLP or its compounds as antioxidant nutrients. In consistent with hypotriglyceridemic effect of OLP found in our results, we speculate also that higher fatty acid oxidation due to the activation of carnitine palmitoyltransferase is responsible for the lower accumulation of body weight by OLP. Our results suggest that the anti-obesity effect of OLP is mediated through oleuropein by a mechanism involving higher fatty acids oxidation. Further study is needed to explain the phenomena by measuring serum free fatty acid and the activity of carnitine palmitoyltransferase as a rate limiting enzyme of mitochondrial fatty acid oxidation and also the activities of enzymes of lipogenesis such as G6PD and FAS.



Value are means  $\pm$  SE (n= 5) for each group

\*Significantly different from control ( $P < 0.05$ ).




Value are means  $\pm$  SE (n= 5) for each group


\*Significantly different from control ( $P < 0.05$ ).

- **Effect of 6.25% OLP (*Chemlali*) on serum Albumine and creatinine**

Dietary addition of 6.25% of OLP significantly caused elevation of serum creatinine and slightly lowered serum albumine (**Fig 14, 15**). The same results were obtained with supplementation of olive leaves extract (*Al-janabi et al., 2015*).



Value are means  $\pm$  SE (n= 5) for each group



Value are means  $\pm$  SE (n= 5) for each group

\*Significantly different from control ( $P < 0.05$ ).



# Conclusion

## CONCLUSION

Obesity is a chronic disease of multifactorial origin that develops from the interaction of lifestyle and genetic factors.

Obesity is not only considered as a disease in itself, but it also gives rise to and aggravates many others, and is thus known to be a risk factor for certain chronic diseases, in particular being closely associated with pathologies like diabetes, cardiovascular diseases, osteoporosis and certain types of cancer (**Rodríguez-Martín, 2009**).

Evidences are emerging to support that an increasing consumption of herbs are effective strategy for obesity control and weight management. For centuries people across the countries have been using natural products as plant based dietary supplements for weight control (**Sekaran *et al.*, 2012**).

It was known that OLE has hypotensive, anti-diabetic and anti-cancer effect that due to its richness by polyphenols and this study provided that feeding 6.25% of OLP significantly decreased serum triglycerides level, visceral fat-pad weights, our study demonstrated that supplementation with OLP is helpful to combat or prevent obesity. The anti-obesity effect was demonstrated by hypotriglyceridemia through a mechanism involving activation of fatty acids oxidation as result reduction of body fat accumulation. Further, this study is needed to measure serum free fatty acid, the activity of lipase, hepatic carnitine palmitoyl transferase (CPT), as a key enzyme of mitochondrial fatty acids oxidation and also the activities of enzymes of lipogenesis such as G6PD and FAS.

In summary, this study showed that consumption of OLP reduces serum triglycerides and abdominal adipose tissues weight (epididimal and perirenal). So, OLP have an anti-obesity effect.

### Literature cited

- Abaza L., Ben Youssef N., Manai H., Haddada F. M., Methenni K., Zarrouk M., (2011). Chétoui Olive Leaf Extracts: Influence of the Solvent Type on Phenolics and Antioxidant Activities. *Grasas y Aceites*. Vol 62 (1), p 96-104.
- Abaza L., Taamalli A., Nsir H and Zarrouk M., (2015). Olive Tree (*Olea europaea* L.) Leaves: Importance and Advances in the Analysis of Phenolic Compounds. *Antioxidants journal*. Vol 4, 682-698.
- Abdalla M. M. I., (2017). Central and Peripheral Control of Food Intake. *Endocrine Regulations*. Vol 51(1), p 52–70.
- Afaneh I., Yateem H., Al-Rimawi F., (2015). Effect of Olive Leaves Drying on the Content of Oleuropein. *American Journal of Analytical Chemistry*. Vol 6, p 246-252.
- Al-Attar A. M., Shawush N. A., (2014). Physiological investigation on the effect of olive live leaves extracts on male rats exposed to thioacetamide. *Saudi Journal Biologic Science*. Vol 21 (5), p 473-480.
- Al-Azzawie H. F., Alhamdani M. S., (2006). Hypoglycemic and Antioxidant Effect of Oleuropein in Alloxan-Diabetic Rabbits. *Life sciences*. Vol 78, p1371 – 1377.
- Alhamd A. K. J., (2015). Improvement Extraction of Crude Compounds from Iraqi Olive Leaves by Applying Water-Base and Alcoholic-Base Extraction and their Biological Application. *World Journal Of Pharmacy And Pharmaceutical Sciences*. Volume 4(1), p183-200.
- Al-Janabi O. S. I., Amer M. S., Khayri M. H., (2015). Effects of The Extracts of Olive Leaves and *Morus Alba* Leaves on Experimentally STZ Induced Diabetes in male Rats. *International Journal of Science and research*. Vol 4(3), p 1526-1532.

## LITERATURE CITED

---

- Almukii N. A., Oyeyemi B. F., (2017). Obesity, Viz a Vis the Gene, Behavioural and Environmental Factors. *Advances in Obesity, Weight Management and Control*. Vol 6.
- Al-Okbi S.Y., Hassan Z. A., El-Mazar M. M., Ammar N. M., Abou El-Kassem L. T., El-Bakry H. F., (2016). Potential Diuretic Activity of Olive Leaf Extracts. *International Pharmacology Technology Research*. Vol 9(9), p 519-533.
- Apovian C. M., Aronne L. J., Bessesen D. H., McDonnell M. E., Murad M. H., Uberto Pagotto U., Ryan D. H., Still C. D., (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. *Clinical Endocrinology Metabolism*. Vol 100(2), p 342–362.
- Bahloul N., Kechaoua N., Mihoub N.B., (2014). Comparative investigation of minerals, chlorophylls contents, fatty acid composition and thermal profiles of olive leaves (*Olea europaeae* L) as by-product. *Grasas Y Aceites*. Vol 65 (3).
- Benavente-Garcia O., Castillo, J., Lorente J., Ortuno A., Del Rio J. A., (2000) Antioxidant activity of phenolics extracted from *Olea europaea* L. leaves. *Food Chemistry*. Vol 68, p 457–462.
- Buccolo G., David H., (1973). Quantitative determination of serum triglycerides by use of enzymes. *Clinical Chemical*. Vol 19 (5), p 476-482.
- Chabowska-Kita A., Kozak L. P., (2016). The Critical Period for Brown Adipocyte Development: Genetic and Environmental Influences. *Obesity Biology And Integrated Physiology*. Vol 24, p 283–290.
- Chang H. C., Yang H. C., Chang H. Y., Yeh C. J., Chen H. H., Huang K. C., Pan W. H., (2017). Morbid Obesity in Taiwan: Prevalence, Trends, Associated Social Demographics, and Lifestyle Factors. *Plos One*. Vol 12(2), p 1-13.
- Chiappetta A., Muzzalupo I., (2012). Chapter2: Botanical description. Olive Germplasm – The Olive Cultivation, Table Olive and Olive Oil Industry. Muzzalupo I., Italy, p 384.

## LITERATURE CITED

---

- Chun-Laam R., Chan K. H., (2017). Potential Neuroprotective Effects of Adiponectin in Alzheimer 's Disease. *International Journal of Molecular Sciences*. Vol 15, p 1-13.
- Committee on Herbal Medicinal Products, 2011.
- Dekanski D., Janićijević-Hudomal S., Tadić V., Marković G., Arsić I., Dušan Mitrović D., (2009). Phytochemical Analysis and Gastroprotective Activity of an Olive Leaf Extract. *The Serbian Chemical Society*. Vol 74 (4), p 367–377.
- Dekdouk N., Malafronte N., Russo D., Faraone I., DeTommasi N., Ameddah S., Lorella Severino L., Milella L., ( 2015). Phenolic Compounds from *Olea europaea L.* Possess Antioxidant Activity and Inhibit Carbohydrate Metabolizing Enzymes In Vitro. *Evidence-Based Complementary and Alternative Medicine*. Vol (2015), p1-9.
- Duncan S., Duncan E. K., Fernandez R. A., Buonani C., Bastos K. D. N., Segatto A. F. M., Codogno J. S., Gomes I. C., Freitas I. F., (2011). Modifiable Risk Factors for overweight and obesity in children and adolescents from São Paulo, Brazil. *BMC public health*. Vol 11, p 1-9.
- Ellulu M., Abed Y., Rahmat A., Ranneh Y., Ali1 F., (2014). Epidemiology of Obesity in Developing Countries: Challenges and Prevention. *Global Epidemic Obesity*. Vol 2(2), p 1-6.
- Erbay Z., Icier F., (2010). The Importance and Potential Uses of Olive Leaves. *Food Reviews International*. Vol 26, p319–334.
- Gambero A., Ribeiro M. L., (2015). The Positive Effects of Yerba Maté (*Ilex paraguariensis*) in Obesity. *Nutrients journal*. Vol 7, p 730-750.
- Gambero A., Ribeiro M. L., (2015). The Positive Effects of Yerba Maté (*Ilex paraguariensis*) in Obesity. *Journal of nutrition*. Vol 7, p 730-750.

## LITERATURE CITED

---

- Gammal M. A., Ibrahim S. R. M., Elkhayat E. S., Salah El Dine R., (2014). Natural Anti-Obesity Agents. *Bulletin of Faculty of Pharmacy*. Vol 52, p 269–284.
- Gottlieb R. J., (2009). Obesity and Cancer. *Lancaster General Hospital*. Vol 4(4), p 143-145.
- Guimarães R., Barros L., Carvalho A. M., Sousa M. J., Sá Morais J., Ferreira I. C. F. R., 2009. Aromatic Plants as a Source of Important Phytochemicals: Vitamins, Sugars and Fatty acids in *Cistus ladanifer*, *Cupressus lusitanica* and *Eucalyptus gunnii* leaves. *Industrial Crops Products*. Vol 30, p 427–430.
- Guinda A., Castellano J. M., Santos-Lozano J. M., Delgado-Hervas T., Gutierrez-Adanez P., Rada M., (2015). Determination of Major Bioactive Compounds from Olive Leaf. *LWT - Food Science and Technology*. p 1-8.
- Gummesson A., (2009). Pathogenesis of Obesity and Effects of Treatment. p 1-49.
- Gurevich-Panigrahi T., Panigrahi S., Wiechec E., Los M., (2009). Obesity: Pathophysiology and Clinical Management. *Current Medicinal Chemistry*. Vol 16, p 506-521.
- Haloui E., Marzouk Z., Marzouk B., Bouftira I., Bouraoui A., Fenina N., (2010). Pharmacological Activities and Chemical Composition of the *Olea europaea L.* Leaf Essential Oils from Tunisia. *Food, Agriculture and Environment*. Vol 8(2). p 204-208.
- Haslam D., (2016). Weight management in obesity – past and present. *The international journal of clinical practice*. Vol 70(3), p 206-217.
- Heymsfield S. B., Wadden T. A., (2017). Mechanisms, Pathophysiology, and Management of Obesity. *The New England Journal of Medicine*. Vol 376, p 254-266.

## LITERATURE CITED

---

- Hruby A., Hu F. B., (2014). The Epidemiology of Obesity: A Big Picture. *Pharmacoeconomics*.
- Jensen M. D., Ryan D. H., Apovian C. M., Loria C. M., Ard J. D., Millen B. E., (2013). A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. *The American heart association*. p 1-70.
- Johansson k., (2012). *very low energy diets in the treatment of obesity*. p 1-59.
- Kaplan L. A. Glucose. Kaplan A., *et al.*, (1984). Glucose. *Clinical Chemical The C.V. Mosby Co. St Louis.Toronto. Princeton*; 1032-1036.
- Karouche S., Rouabah A., Rouabah L., Necib Y., (2013). Epidemiological Approach to Overweight in the Town of Ain Fakroun in 2012 (east of Algeria). *American Journal of Life Sciences*. Vol 1(5), p 232-237.
- Kawashima K., Maeda K., Saigo C., Kito Y., Yoshida K., Takeuchi T (2017). Adiponectin and Intelectin-1: Important Adipokine Players in Obesity-Related Colorectal Carcinogenesis. *Internationnal Journal of Molecular Science*. Vol 18, p 1-12.
- Kawsar S. M. A., Huq E., Nahar E. N., Ozeki Y., (2008). Identification and Quantification of Phenolic Acids in *Macrotylomauniflorum* by Reversed Phase-HPLC. *American Journal of Plant Physiology*. Vol 3, p 165-172.
- Kazan M., Karalti I., (2015). The Association between Obesity and Cancer. Vol 4, p 1-13.
- Laaboudi W., Ghanam J., Ghoumari O., Sounni F., Merzouki M., Benlemlih M., (2016). Hypoglycemic and Hypolipidemic Effects of Phenolic Olive Tree Extract in Streptozotocin Diabetic Rats. *International Journal of Pharmacy and Pharmaceutical Sciences*. Vol 9(9), p519-533.

## LITERATURE CITED

---

- Leal V. O, Mafra D., (2013). Adipokines in obesity. *Clinical Chimical Acta*. Vol 419, p 87–94.
- Lee-Huang S., Huang P. L., Zhang D., Lee J. W., Chang Y. T., Zhang J. and Huang P.L (2013). Oleuropein and Related Compounds from Olive Plants Modulate Adipogenesis. *The Open Conference Proceedings Journal*. Vol 4, p 113-124.
- Liao C., Gao W., Cao W., Lv J., Yu C., Wang S. F., Zhou B., Pang Z. C., Cong L., Wang H., Wu X., Li L., (2015). Associations of Body Composition Measurements with Serum Lipid, Glucose and Insulin. *Plose one*. Vol 10(11), p 1-16.
- Liguri G., Stefani M., (2017). Recent Advances in Basic and Clinical Research on the Prevention and Treatment of the Metabolic Syndrome and Related Disorders by the use of Olive Polyphenols. *Genitics and Genomics*, Vol 65, p 48-58.
- Luo J. J., Dun N. D., (2012). New Research Advances in Obesity: Relevant to Neurologic Disorders. *Brain Disorders & Therapy*. Vol 1(2), p 1-2.
- Mahmoudi S., Khali M., Benkhaled A., Benamirouche K., Baiti I., (2016). Phenolic and Flavonoid Contents, Antioxidant and Antimicrobial Activities of Leaf Extracts from Ten Algerian *Ficus carica* L. varieties Asian Pacific. *Tropical Biomedicine*. Vol 6(3), p 239–245.
- Majanović S. K., Orlić Z. C., Štimac D., (2016). Current Trends in the Pharmacotherapy for Obesity. *Endocrine Oncology and Metabolism*. P 50-59.
- Meiatini, F., et al., (1978) the 4-hydroxybenzoate/4-aminophenazone Chromogenic System. *Clinical Chemical*; 24 (12): 2161-2165.
- Moghaddam M. G., Masomi Y., Razavian M., Moradi M., (2013). The Effect of Oral Consumption of Olive Leaves on Serum Glucose Level and Lipid Profile of Diabetic Rats. *Basic and clinical pathophysiology*. Vol 1(2). p 39-44.



## LITERATURE CITED

---

- Mosleh G., Mohagheghzadeh A., Faridi P., (2016). Olive leaf: From tradition to clinic. *Trends in Pharmaceutical Sciences*. Vol 2(4), p 241-252.
- Mourtizinos I., Salta F., Yannakopoulou K., Chiou A., Karathanos V. T., (2007). Encapsulatrion of Olive Leaf Extract in Cyclodextrin. *Agriculture Food Chemistry*. Vol 55(20), p 8088-8094.
- Mousa H. M., Farahna M., Ismail1 M. S., Al-Hassan A. A., Ammar A. S., Abdel-Salam A. M., (2014). Anti-diabetic Effect of Olive Leaves Extract in Alloxan-Diabetic Rat. *Agricultural and Veterinary Sciences*. Vol 7(2), p181-196.
- Moussaoui R., Siziani D., Youyou A., Sharrock P., Fiallo M. M., (2010). Antioxidant Effect of Phenolic Compounds Recovred from Olive Mill Wastewater of *Chemlali* Variety Cultivated in Kabylia (Algeria) on The Oxidative Stability of Virgin Olive Oil. *Journal of Food, Agriculture and Environment*. Vol 8 (3&4), p 86-89.
- Murray R. L., Kaplan A., (1984). Creatinine. *ClinChemThe C.V. Mosby Co. St Louis.Toronto. Princeton*. Vol (418), p 1261-1266.
- Naito H., High-density lipoprotein (HDL) cholesterol. Kaplan A., et al., (1984). *ClinChemThe C.V. Mosby Co. St Louis. Toronto. Princeton*. Vol (437), p 1207-1213.
- Narayana K. S., Koora S., Sivarajasundari G. T., Shaker A., (2013). Dose Dependent Effect of Olive Leaves Extract on Inflammatory Cyclooxygenase (COX) Levels in High Fat Diet (HFD) Induced Diabetic Animals. *International journal of Scientific Research*. Vol 2(3), p 324-326.
- Nashwa F. S., Morsy M. E., (2014). Efficiency of Olive (*Olea europaea L*) Leaf Extract as Antioxidant and Anticancer Agents. *Agroalimentary Processes and Technologies*. Vol 20(1), p 46-53.

## LITERATURE CITED

---

- Olayinka E. T., Ore A., Adeyemo O. A., Ola O. S., Olotu O. O., Echebiri R. C., (2015). Quercetin, a Flavonoid Antioxidant, Ameliorated Procarbazine-Induced Oxidative Damage to Murine Tissues. *Antioxidant journal*. Vol 4, p 304-321.
- Omar S. H., (2010). Oleuropein in Olive and its Pharmacological Effects. *Scientia pharmaceutica*. Vol 78, p 133–154.
- Ouchi N., Parker J. L., Lugus J. J., Walsh K., (2011). Adipokines in Inflammation and Metabolic Disease. *Focus on Metabolism and Immunology*. Vol 11, p 85-97.
- Panigrahi T. G., Panigrahi S., Wiechec E., Los M., (2009). Obesity: Pathophysiology and Clinical Management. *Current Medicinal Chemistry*. Vol 16, p 506-521.
- Patel D., (2015). Pharmacotherapy for the management of obesity. *Metabolism Clinical and experimental*.
- Pem D., Jeewon R., (2015). Fruit and Vegetable Intake: Benefits and Progress of Nutrition Education Interventions- Narrative Review Article. *Iran Journal Public Health*. Vol 44(10), p 1309-1321.
- Pepper M. S., Logan M. G., (2010). The genetics of obesity: the role of the melanocortin 4 receptor. *Endocrinology, Metabolism and Diabetes of South Africa*. Vol 15(1), p 45-47.
- Perry I. J., (2015). Obesity: A societal responsibility. *Obesity Facts the European journal of obesity*.
- Peyrol J., Riva C., Amiot M. J., (2017). Hydroxytyrosol in the Prevention of the Metabolic Syndrome and Related Disorders. *Nutrients Journal*. Vol 9 (306), p 1-18.
- Price S., Proietto J., (2015). Is Obesity a Chronic Disease?. p 69-82.

## LITERATURE CITED

---

- Qadir N. M., Khabat A. A., Qader S. W., (2016). Antidiabetic Effect of Oleuropein from *Olea europaea* Leaf against Alloxan Induced Type 1 Diabetic in Rats. *An International Journal of Brazilian Archives of Biology and Technology*. Vol 59, p 1-10.
- Rodríguez-Martín A., Novalbos Ruiz J. P., Martínez Nieto J. M., Jiménez E., (2009). Life-style factors associated with overweight and obesity among Spanish adults. *Nutrition Hospitaria*. Vol 24(2), p 144-151.
- Romieu I., Barquera L. D. S., Blottière H. M., Franks P. W., Marc Gunter M., Hwalla N., Hursting S. D., Leitzmann M., Margetts B., Nishida C., Potischman N., Stepien J. S. M., Wang Y., Westerterp K., Winichagoon P., Wiseman M., Willett W. C., (2017). Energy balance and obesity: what are the main drivers?. *Cancer Causes Control*. Vol (28), p 247–258.
- Rowland T.W (2007). Effect of Obesity on Cardiac Function in Children and Adolescents: A Review. *Sports Science and Medicine*. Vol 6, p 319-326.
- Sabry O. M. M., (2014). Review: Beneficial Health Effects of Olive Leaves Extracts. *Journal of Natural Sciences Research*. Vol 4(19), p 1-9.
- Santi-Cano M. J., (2014). Obesity and Cardiovascular Risk Factors. *Obesity and Control Therapies*. Vol 1(1), p 1-9.
- Satya Narayana K., Koora S., Sivarajasundari G. T., Shaker A., (2013). Dose Dependent Effect of Olive Leaves Extract on Inflammatory Cyclooxygenase (COX) Levels in High Fat Diet (HFD) Induced Diabetic Animals. *Medical Science*. Vol 2(3), p 324-326.
- Scott F. I., Horton D. B., Mamtani R., Haynes K., Goldberg D. S., Lee D. Y., Lewis J.D., (2016). Etiology and Comorbidities of Childhood Obesity. *Turk Journal Gastroenterol*. Vol 28, p 149-151.

## LITERATURE CITED

---

- Sedef N. E., Sibel K., (2009). Olive Tree (*Olea europaea*) Leaves: Potential Beneficial Effects on Human Health. *International Life Sciences Institute*. Vol 67(11). p 632-638.
- Shen Y., Song S. J., Keum N., Park T., (2013). Olive Leaf Extract Attenuates Obesity in High-Fat Diet-Fed Mice by Modulating the Expression of Molecules Involved in Adipogenesis and Thermogenesis. *Evidence-Based Complementary and Alternative Medicine*. p 1-12.
- Silva S., Gomes L., Leitão F., Coelho A. V., Vilas Boas L., (2006). Phenolic Compounds and Antioxidant Activity of *Olea europaea*. Fruits and Leaves. *Food Science Technology International*. Vol 12(5), 385–396.
- Talal A., Zari A., Al-attar M., (2011). Therapeutic Effects of Olive Leaves Extract on Rats Treated with a Sublethal Concentration of Carbendazim. *European Review for Medical and Pharmacological Sciences*. Vol 15, p 413-426.
- Taleb S., Oulamara H., Agli A. N., (2012). Change in the Prevalence of Overweight and Obesity among School Children in Tebessa (Eastern Algeria) between 1995 and 2007. *Obesity and Weight loss Therapy*. Vol 2(1), p 1-4.
- Tanveer M. A., Chaudhary G. M., Fawwad A., Mustafa N., Khalid M., Shafi A., (2017). Factors Predicting Dyslipidemia in Obese Type 2 Diabetic Subjects. *British Journal of Medicine & Medical Research*. Vol 20(8), p 1-6.
- Tehmina A. T., Mercer J. G., (2016). Hunger and Satiety Mechanisms and Their Potential Exploitation in the Regulation of Food Intake. *Psychological Issues*. Vol 5, p 106–112.
- Vassallo J., (2007). Pathogenesis of obesity. *The Malta College of Pharmacy Practice*. Vol 12, p 19-22.

## LITERATURE CITED

---

- Vogel P., Machado I. K., Garavaglia J., Zani V. T., Souza D., Dal Bosco S. M., (2015). Polyphenols Benefits of Olive Leaf (*Olea europaea* L) to Human Health. *Nutrition Hospitalaria*. Vol 31(3). p 1427-1433.
- Wainstein J., Ganz T., Boaz M., Bar Dayan Y., Dolev E., Kerem Z., Madar Z., (2011). Olive Leaf Extract as a Hypoglycemic Agent in Both Human Diabetic Subjects and in Rats. *Medicinal Food*. Vol 15 (7), p 1–6.
- Xie X., Man X., Zhu Z., Dejian Yuan D., Huang S., (2016). Tumor Suppressor RIZ1 in Obesity and the PI3K/AKT/mTOR Pathway. *Obesity Biology and Integrated Physiology*. Vol 24, p 389–397.
- Yancheva S., Mavromatis P., Georgieva L., (2016). Polyphenol Profile and Antioxidant Activity of Extracts from Olive Leaves. *Central European Agriculture*. Vol 17(1), p154-163.
- Yateem H., Afaneh I., Al-Rimawi F., (2014). Optimum Conditions for Oleuropein Extraction from Olive Leaves. *International Journal of Applied Science and Technology*. Vol4 (5), p 153-157.
- Zoair M. A., (2014). A Possible Antioxidant Effect of Olive Leaf Extraction in Diabetic Rats. *Global Journal of Scientific Research*. Vol 2(6), p165-170.

**Abstract:**

Olive tree (*Olea europaea*) is one of the most important fruit trees in Mediterranean countries. In Algeria, olive tree is one of the most important tree cultivated, whereas variety of *Chamlali* is the most spread wideolive tree. Olive leaves (OL) have the highest antioxidant among the different others parts of olive tree. OL have been used in traditional medicine to lower hypertension and diabetes and both of diseases are associated with obesity.

This study aimed to examine the effect of dietary addition of 6.25% of *Olea europaea* leaves variety *chamlali* powder (OLP) on serum lipids level and fat accumulation. Rats were fed for 5 weeks diets with or without 6.25% of OLP.

Supplemented diet with 6.25% of OLP caused reduction of 37%, 45% in relative epididymal and perirenal adipose tissue weight respectively. OLP also caused 32.60% decreasing in serum triglyceride concentration.

This study showed that 6.25% of OLP have an anti-obesity effect by reducing fat accumulation through a mechanism involving its active compounds such as oleuropein

**Keywords:** *Olea europaea* leaves, hypotriglyceridemia, adipose tissue, obesity.

## **Résumé:**

L'Olivier (*Olea europaea*) est l'un des arbres fruitiers les plus importants dans les pays méditerranéens. En Algérie, l'olivier est l'un des arbres les plus cultivés et les plus importants, dont la variété de Chamlali est la variété la plus répartie. Les feuilles d'olives ont la quantité des antioxydants la plus élevée parmi les différentes autres parties d'olivier. Les feuilles d'olive ont été utilisées dans la médecine traditionnelle pour baisser l'hypertension et atténuer le diabète et les deux maladies associées avec l'obésité.

Cette étude a eu pour but d'examiner l'effet de régime alimentaire 6.25 % de la poudre des feuilles d'*Olea europaea* variété Chamlali sur le niveau de lipides sériques et l'accumulation des grasses. Les rats ont été alimentés pour régimes pendant 5 semaines avec ou sans 6.25 % de la poudre des feuilles d'olive.

Le régime Complété avec 6.25 % de la poudre des feuilles d'olive a causé la réduction de 37 %, 45 % dans le poids du tissu adipeux épididymaire relatif et le poids du tissu adipeux péricardiaque respectivement, les feuilles d'olives provoquent aussi une diminution de 32.60 % dans la concentration sérique de triglycérides.

Cette étude a montré que 6.25 % de la poudre des feuilles d'olive pourraient être ont un effet d'anti-obésité en réduisant l'accumulation des grasses par un mécanisme impliquant ses composés actifs comme oleuropeine ou d'autres composés comme les fibres.

**Mots-clés:** les feuilles d'*Olea europaea*, hypotriglyceridemia, tissu adipeux, obésité.

## ملخص:

شجرة الزيتون من أهم و اغلب الاشجار المزروعة في بلدان البحر الابيض المتوسط. يعد نوع الشماللي من انواع اشجار الزيتون الاكثر انتشارا في الجزائر. تعتبر اوراق الزيتون الاغنى من حيث مضادات الاكسدة مقارنة بالاجزاء الاخرى لشجرة الزيتون و هذا لوفرة المركبات الفينولية بها. تستعمل اوراق الزيتون في الطب التقليدي لعلاج ارتفاع ضغط الدم و داء السكري, كل من هذه الامراض تعتبر من خلفيات مرض السمنة.

لذا هذه الدراسة تهدف لفحص تأثير 6.25% من مسحوق اوراق الزيتون على نسبة الدهون في الدم و تراكم الدهون في الجسم. تم علف الجردان بغذاء مع او بدون مسحوق اوراق الزيتون لمدة خمسة اسابيع.

إضافة 6.25% من مسحوق اوراق الزيتون لغذاء الجردان ادى الى تخفيض الوزن النسبي للنسيج الدهني البرنخي بنسبة 37%, و النسيج الدهني المحيط بالكلى بنسبة 45%, و تخفيض تركيز الغليسيريدات الثلاثية بنسبة 32.60%.

هذه الدراسة أظهرت أن 6.25% من مسحوق اوراق الزيتون له تأثير مضاد للسمنة وذلك بخفض الغليسيريدات الثلاثية تراكم الدهون من خلال الية تقحم المركب الاساسي في أوراق الزيتون.

**الكلمات المفتاحية :** أوراق الزيتون , الغليسيريدات الثلاثية, النسيج الدهني, السمنة



Academic year : 2016-2017

Done by : ATHAMNA FATIMA

BENOUCHENNE DJAMILA

Dissertation to get Diploma of Master in  
Molecular Nutrition and Health

### Anti-obesity Effect of Olive Leaves Powder

**Abstract:**

Olive tree (*Olea europaea*) is one of the most important fruit trees in Mediterranean countries. In Algeria, olive tree is one of the most important tree cultivated, whereas variety of *Chamlali* is the most spread wide olive tree. Olive leaves (OL) have the highest antioxidant among the different others parts of olive tree. OL have been used in traditional medicine to lower hypertension and diabetes and both of diseases are associated with obesity.

This study aimed to examine the effect of dietary addition of 6.25% of *Olea europaea* leaves variety *chamlali* powder (OLP) on serum lipids level and fat accumulation. Rats were fed for 5 weeks diets with or without 6.25% of OLP.

Supplemented diet with 6.25% of OLP caused reduction of 37%, 45% in relative epididymal and perirenal adipose tissue weight respectively. OLP also caused 32.60% decreasing in serum triglyceride concentration.

This study showed that 6.25% of OLP have an anti-obesity effect by reducing fat accumulation through a mechanism involving its active compounds such as oleuropein.

**Keywords:** *Olea europaea*, hypotriglyceridemia, adipose tissue, obesity.

**Reaserch Laboratory:** Biochemistry Laboratory, Military Hospital. Constantine

**Examination Board:**

**President:** Dr. Y. NECIB

Pr. University of Brothers MENTOURI Constantine 1

**Supervisor:** Dr. A. KHEDARA

M. C. A University of Brothers MENTOURI Constantine1

**Examiner:** Dr. T. NOUADRI

M. C. A University of Brothers MENTOURI Constantine1

**Date of presentation:** July 6<sup>th</sup>, 2017